Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Pennsylvania for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Pennsylvania only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Pennsylvania (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Sarah Coleman (NPI 1700083581)

Field	Value
Entity Type	Individual
Organization	Sarah Coleman
Address	2360 Maryland Rd
City	Willow Grove
State	PA
ZIP	19090
Taxonomy	Rheumatology Physician
NPI Enumerated	June 27, 2007

Payer Source	Total Paid
Medicare	$2.4M
Medicaid	$0

Key Findings

SARAH COLEMAN is a Rheumatology Physician in WILLOW GROVE, PA with lifetime Medicare revenue of $2.4M and no Medicaid billing on file, making her practice effectively single-payer (Medicare) in scale. Her NPI was enumerated 2007-06-27 (~19 years ago), indicating long-standing enrollment in the Medicare program. This payer concentration has implications for network negotiations and population access metrics focused on Medicare beneficiaries.

Revenue is highly concentrated in biologic drug administration: the top three Medicare codes drive nearly half of Medicare revenue, with the precomputed top-3 share at 47.6%. Those top codes are J0897 ($425.5K revenue, 17.2%), J3262 ($392.6K revenue, 15.9%), and J0129 ($360.4K revenue, 14.6%), underscoring that injected/infused specialty pharmaceuticals are the primary revenue drivers. This concentration suggests the practice’s financial performance is sensitive to utilization and reimbursement changes for a small set of biologic agents.

The code mix indicates an infusion- and injection-centric rheumatology practice: high-value biologics such as J0897 (denosumab), J3262 (tocilizumab), J0129 (abatacept), J1602 (golimumab), J1745 (infliximab), and J9312 (rituximab) appear prominently in revenue rankings. Complementary administration and chemotherapy/infusion CPTs (96413, 96401, 96365, 96366) and in-office E/M visits (99214, 99213) imply on-site infusion services with associated chair time and clinical staffing. Together these codes point to a clinic model that performs buy-and-bill or physician-administered specialty drug services rather than primarily prescribing self-administered therapies.

Competitive standing is mixed across specific therapies: J0897 is an extreme outlier nationally (rank #189 of 10057, 98th percentile), indicating unusually high denosumab volume compared with peers. J3262 ranks #100 of 618 (84th percentile) and J0129 ranks #441 of 1221 (64th percentile), meaning the provider is a high-volume tocilizumab administrator and a moderate-volume abatacept administrator relative to national cohorts. For certain service lines the provider appears to be a major national participant (denosumab) while other biologics show more typical or modest standing.

Operational patterns show very large claim counts with low average paid per claim for some biologics, consistent with high-frequency dispensing: J3262 lists 78.5K claims at $5 avg paid/claim, J0897 lists 23.6K claims at $18 avg paid/claim, and J0129 lists 10.6K claims at $34 avg paid/claim. These data suggest administrative scale in drug handling, inventory management, and potential cash-flow considerations associated with buy-and-bill operations. The presence of numerous infusion administration CPTs (96413, 96401, 96365) further supports the need for infusion-suite operational capacity.

Service-volume signals extend beyond injectable drugs: office visit code 99214 generates $83.2K (849 claims) and ranks #17002 of 479517 (96th percentile), indicating above-typical Medicare outpatient visit activity for the practice. Additionally, 96401 (subcutaneous/IM chemotherapy administration) ranks #114 of 3868 (97th percentile), reinforcing that procedural administration services are notable contributors to clinical throughput. Together these suggest a balanced revenue mix of procedure-driven drug administration and higher-complexity outpatient visits.

Given the provider’s Medicare-only exposure and concentrated revenue in specialty injectables—particularly an extreme outlier position for J0897—payers and provider-affiliation analysts should prioritize targeted reviews of utilization patterns, site-of-care appropriateness, and documentation for infusion services. Monitoring should focus on the high-volume biologic codes and associated administration CPTs to assess clinical appropriateness, referral pathways, and potential impacts of changes in Medicare reimbursement or policy for physician-administered drugs.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

25 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0897	Injection, denosumab, 1 mg	23,640	$20	$425.5K
J3262	Injection, tocilizumab, 1 mg	78,520	$10	$392.6K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	10,600	$30	$360.4K
J1602	Injection, golimumab, 1 mg, for intravenous use	21,050	$10	$231.6K
J1459	Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg	5,090	$40	$188.3K
J3111	Injection, romosozumab-aqqg, 1 mg	22,470	$10	$179.8K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	41,200	$1	$164.8K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	6,100	$30	$158.6K
J9312	Injection, rituximab, 10 mg	1,950	$60	$124.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	850	$100	$83.2K

Showing 1–10 of 25

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 25 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Pennsylvania Distribution

Sarah Coleman — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Pennsylvania

Full comparison — all codes billed, vs. state median

25 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	19	60	7,900	$30	$353.8K
J3262	8	30	45,000	$1	$268K
J0717	31	70	38,610	$1	$223.7K
J9312	9	10	2,330	$60	$192K
J1602	13	60	11,780	$10	$181.6K
J3111	17	60	16,590	$10	$176.8K
J1745	18	80	3,630	$30	$115.4K
J1459	1	10	3,070	$40	$114.2K
J0897	11	530	2,460	$20	$89.6K
96413	17	300	140	$100	$19.8K

Showing 1–10 of 25

Related Providers

Other providers that share a Tax Identification Number (TIN) with Sarah Coleman, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Dennis Jerdan	PA	Rheumatology Physician	$2.5M	$0
Elana Eisner	PA	Rheumatology Physician	$2.1M	$0
Charles Pritchard	PA	Rheumatology Physician	$2.1M	$0
David Chesner	PA	Rheumatology Physician	$1.6M	$0
Marguerite Mcgarvey	PA	Rheumatology Physician	$1.5M	$0
Dana Jacobs-kosmin	PA	Rheumatology Physician	$1.4M	$0
Monica Mohile	PA	Rheumatology Physician	$1.4M	$0
Thomas Quinn	PA	Rheumatology Physician	$883.9K	$0
Stephanie Morris	PA	Rheumatology Physician	$742.6K	$0
Anjali Bal	PA	Internal Medicine Physician	$731.1K	$0

Nearby Providers

Other providers in the same ZIP code as Sarah Coleman, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Bayada Home Health Care, Inc.	PA	Home Health Agency	$0	$16M
Central Behavioral Health	PA	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$8.6M
Second Alarmer's Assn & Rescue Squad Of Montgomery County Inc	PA	Paramedic	$1.2M	$1.8M
Montgomery County Advanced Medical Imaging, LLC	PA	Clinic/Center	$1M	$0
Sally Pullman-mooar	PA	Rheumatology Physician	$752.4K	$0
Abington Surgical Center	PA	Ambulatory Surgical Clinic/Center	$653.8K	$0
Kevin Lu	PA	Internal Medicine Physician	$626K	$0
Chad Krueger	PA	Orthopaedic Surgery Physician	$358.1K	$0
Joshua Goldberg	PA	Otolaryngology Physician	$232.1K	$2.3K
Victor Ghantous	PA	Nephrology Physician	$205.9K	$0

Sarah Coleman — Billing Profile & Reimbursement Data

Sign up for Sarah Coleman — Billing Profile & Reimbursement Data policy alerts

Sarah Coleman — Billing Profile & Reimbursement Data

Sign up for Sarah Coleman — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References